US FDA approves AstraZeneca's Farxiga to treat type 2 diabetes

9 January 2014

Reversing a previous 2012 negative decision, the US Food and Drug Administration yesterday (January 8) approved Anglo-Swedish drug major’s AstraZeneca’s (LSE: AZN) dapagliflozin, (proposed US trade name Farxiga), to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.

Dapagliflozin, an SGLT2 inhibitor to which AstraZeneca is gaining full rights under its recent diabetes assets deal with partner Bristol-Myers Squibb (NYSE: BMY; The Pharma Letter December 20, 2013), is already approved in the 28 member states of the European Union, where it carries the brand name Forxiga, and in Argentina, Australia, Brazil, Iceland, Mexico.

Decision follows recent advisory panel backing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK